Jaydira Del Rivero | Medical Oncology | Best Researcher Award

Posted on by ScienceFather

Dr. Jaydira Del Rivero | Medical Oncology | Best Researcher Award

MD of NCI/NIH, United States.

Dr. Jaydira Del Rivero has a robust set of research skills tailored for oncology. Her expertise includes cell culture, immunohistochemistry, CRISPR/Cas9 gene editing, and advanced microscopy. Proficient in data analysis using SPSS and R, she excels in bioinformatics for genomic data. Dr. Del Rivero is adept at experimental design, critical literature evaluation, and communicating scientific results.

Professional Profiles:

Education

Dr. Jaydira Del Rivero earned her Doctor of Medicine (MD) degree from the University of Veracruz, Faculty of Medicine “Lic. Miguel Aleman Valdez” in October 2003. She completed her Internal Medicine residency at Woodhull Medical and Mental Health Center/NYU Langone Medical Center in Brooklyn, NY, from July 2008 to June 2011. Following this, she pursued a fellowship in Endocrinology, Diabetes, and Metabolism at the Inter-Institute Adult Endocrine Training Program at the National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, from July 2011 to June 2014. Dr. Del Rivero further specialized in Medical Oncology through a fellowship at the National Cancer Institute, National Institutes of Health, Bethesda, MD, from July 2015 to June 2017. Her extensive training reflects her deep commitment to advancing in both endocrinology and oncology.

Professional Experience

Dr. Jaydira Del Rivero has held several notable positions in the medical field. She began her career as a Medical Officer at the National Institute of Child Health and Human Development from August 2014 to June 2015, where she focused on endocrine research. Following her fellowship in Medical Oncology, she joined the National Cancer Institute (NCI) as a Clinical Fellow in the Medical Oncology Branch from July 2015 to June 2017. Since 2017, Dr. Del Rivero has been a Medical Oncologist at the NCI, specializing in the treatment and research of cancer. Her role involves clinical practice, patient management, and contributing to ongoing research efforts. Dr. Del Rivero’s work is pivotal in advancing the understanding and treatment of oncology-related conditions.

Research Interest

Dr. Jaydira Del Rivero’s research interests are centered around oncology, with a particular focus on advancing the understanding and treatment of cancer. Her work primarily explores endocrine-related malignancies, including the development of novel therapeutic strategies and treatment protocols. Dr. Del Rivero is involved in researching the mechanisms of cancer progression and resistance to treatments, aiming to improve patient outcomes through innovative approaches. Her research also encompasses the evaluation of new drugs and treatment regimens, with a commitment to integrating clinical findings with experimental data to enhance therapeutic efficacy. Through her work at the National Cancer Institute, she contributes to cutting-edge studies that aim to address critical challenges in cancer care and therapy.

Award and Honors

Dr. Jaydira Del Rivero has received several notable awards and honors for her contributions to oncology research. She was recognized with the prestigious NCI Director’s Award in 2021 for her exceptional work in cancer research and her commitment to advancing treatment options. In 2019, she earned the American Association for Cancer Research (AACR) Scholar Award, which acknowledged her innovative research on endocrine-related cancers. Additionally, Dr. Del Rivero was honored with the National Cancer Institute’s Outstanding Research Award in 2018 for her impactful studies on novel therapeutic strategies. Her achievements reflect her dedication to improving cancer care and her significant contributions to the field of oncology.

 Research Skills

Dr. Jaydira Del Rivero possesses advanced research skills essential for her work in oncology. She is proficient in various laboratory techniques including cell culture, immunohistochemistry, and molecular cloning. Her expertise extends to cutting-edge methods such as CRISPR/Cas9 gene editing and advanced microscopy techniques. Dr. Del Rivero is skilled in data analysis and statistical software such as SPSS and R, which she utilizes for interpreting complex research data. She also has experience with bioinformatics tools for genomic data analysis, enabling her to identify novel biomarkers and therapeutic targets. Her research skills are complemented by a strong ability to design and conduct experiments, critically evaluate scientific literature, and effectively communicate findings through publications and presentations.

Publications
  1. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity
    Authors: E Wong, LS Rosen, M Mulay, A VanVugt, M Dinolfo, C Tomoda, …
    Journal: Thyroid
    Year: 2007
    Volume/Issue: 17 (4), 351-355
    Citations: 238
  2. The Bethesda handbook of clinical oncology
    Authors: J Abraham, JL Gulley
    Publisher: Lippincott Williams & Wilkins
    Year: 2022
    Citations: 158
  3. Anti–PD-L1 treatment induced central diabetes insipidus
    Authors: C Zhao, SH Tella, J Del Rivero, A Kommalapati, I Ebenuwa, J Gulley, …
    Journal: The Journal of Clinical Endocrinology & Metabolism
    Year: 2018
    Volume/Issue: 103 (2), 365-369
    Citations: 104
  4. Tyrosine kinase inhibitor–induced thyroid disorders: a review and hypothesis
    Authors: N Makita, T Iiri
    Journal: Thyroid
    Year: 2013
    Volume/Issue: 23 (2), 151-159
    Citations: 99
  5. Resection versus expectant management of small incidentally discovered nonfunctional pancreatic neuroendocrine tumors
    Authors: AM Rosenberg, P Friedmann, J Del Rivero, SK Libutti, AM Laird
    Journal: Surgery
    Year: 2016
    Volume/Issue: 159 (1), 302-310
    Citations: 93
  6. Phenotypic and genotypic characterization and treatment of a cohort with familial tumoral calcinosis/hyperostosis‐hyperphosphatemia syndrome
    Authors: MS Ramnitz, P Gourh, R Goldbach‐Mansky, F Wodajo, S Ichikawa, …
    Journal: Journal of Bone and Mineral Research
    Year: 2016
    Volume/Issue: 31 (10), 1845-1854
    Citations: 87
  7. The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and management of metastatic and/or unresectable pheochromocytoma and paraganglioma
    Authors: L Fishbein, J Del Rivero, T Else, JR Howe, SL Asa, DL Cohen, PLM Dahia, …
    Journal: Pancreas
    Year: 2021
    Volume/Issue: 50 (4), 469-493
    Citations: 77
  8. Novel insights into the polycythemia–paraganglioma–somatostatinoma syndrome
    Authors: R Därr, J Nambuba, J Del Rivero, I Janssen, M Merino, M Todorovic, …
    Journal: Endocrine-Related Cancer
    Year: 2016
    Volume/Issue: 23 (12), 899-908
    Citations: 76
  9. Endocrine‐related adverse events related to immune checkpoint inhibitors: Proposed algorithms for management
    Authors: J Del Rivero, LM Cordes, J Klubo‐Gwiezdzinska, RA Madan, LK Nieman, …
    Journal: The Oncologist
    Year: 2020
    Volume/Issue: 25 (4), 290-300
    Citations: 72
  10. Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report
    Authors: JE Faris, AF Moore, GH Daniels
    Journal: Thyroid
    Year: 2007
    Volume/Issue: 17 (11), 1147-1149
    Citations: 72